Giant Axonal Neuropathy (GAN) Market to Grow Rapidly Through Gene Therapy Advancements

Giant Axonal Neuropathy (GAN) Market to Grow Rapidly Through Gene Therapy Advancements

The Giant Axonal Neuropathy (GAN) market is centered on orphan disease therapies aimed at correcting mutations in the GAN1 gene, which causes progressive nerve degeneration, muscle weakness, and impaired motor function. Key offerings include adeno-associated virus (AAV)‐based gene therapies, small‐molecule modulators, and advanced genetic testing kits. Gene therapies deliver functional GAN1 copies directly to neurons, offering potential one‐time treatments with durable efficacy. Small molecules target downstream pathways to slow disease progression, while diagnostic assays enable early detection and personalized care. Advantages of these products include high specificity, reduced systemic toxicity, and the ability to address the root genetic cause rather than merely managing symptoms.

Growing patient registries and enhanced newborn screening programs underscore the urgent need for targeted Giant Axonal Neuropathy (GAN) Market interventions, driving investment and accelerating clinical research. Collaboration between biotech firms and academic centers has streamlined vector design, manufacturing scale‐up, and regulatory filings. As awareness of rare neurological disorders improves, payers are recognizing the long‐term cost benefits of curative approaches versus chronic care.

According to CoherentMI, The giant axonal neuropathy (GAN) Market is estimated to be valued at USD 126.4 Mn in 2025 and is expected to reach USD 186.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Key Takeaways

Key players operating in the Giant Axonal Neuropathy (GAN) Market are:

-Applied Genetic Technologies Corporation (AGTC)

-Audentes Therapeutics (acquired by Astellas Pharma)

-Passage Bio

-Voyager Therapeutics

These firms lead in AAV vector innovation, clinical trial enrollment, and strategic licensing. AGTC and Audentes leverage proprietary capsids to enhance neuronal tropism, while Passage Bio and Voyager focus on scalable manufacturing and global trial expansion. Collaboration agreements with contract development organizations ensure streamlined supply chains and regulatory compliance.

Rising prevalence of inherited neuropathies and increased genetic screening have amplified demand for GAN therapies. Patient advocacy groups and rare disease networks facilitate early diagnosis and trial participation. Moreover, the high unmet medical need—driven by rapid disease progression and lack of approved treatments—motivates healthcare providers and payers to support accelerated approval pathways. Enhanced reimbursement frameworks for orphan drugs further incentivize manufacturers to invest in late‐stage development and market access strategies.

Technological advancements are transforming the GAN landscape through next‐generation sequencing, CRISPR‐based gene editing, and precision vector engineering. Improved AAV capsid libraries boost delivery efficiency and minimize immunogenicity, while novel promoters enable cell‐type–specific gene expression. Digital monitoring tools, including wearable sensors and telemedicine platforms, optimize patient follow-up and real-world evidence generation. Combined, these innovations accelerate bench‐to-bedside transitions and expand therapeutic possibilities beyond traditional gene replacement.

Market Trends

One key trend is the surge in strategic collaborations between biotech firms and large pharmaceutical companies to co‐develop AAV‐based GAN therapies. These partnerships pool resources for preclinical validation, manufacturing scale-up, and global regulatory filings, reducing time to market. A second trend is the expansion of compassionate use and early access programs in regions with limited clinical trial presence. By offering investigational treatments to eligible patients under monitored protocols, developers gather valuable safety and efficacy data while addressing ethical imperatives for rare disease care.

Market Opportunities

Emerging economies present a significant growth opportunity as healthcare infrastructure and rare disease awareness improve across Asia-Pacific and Latin America. Establishing local manufacturing hubs and regulatory support can enhance patient access and reduce treatment costs. Another opportunity lies in novel delivery platforms—such as lipid nanoparticle formulations and exosome‐mediated gene transfer—that may overcome current AAV limitations, expand dosing flexibility, and enable re-dosing in patients with preexisting immunity. These innovations can broaden the GAN treatment paradigm and attract new entrants.

Impact of COVID-19 on Giant Axonal Neuropathy Market Growth

The global outbreak of COVID-19 in early 2020 disrupted multiple facets of the rare genetic disorder sector, including research activities, patient enrollment in clinical trials, and logistical chains for diagnostic reagents and investigational therapies. Pre-pandemic, research centers maintained steady recruitment and saw consistent funding allocation toward rare neuronal conditions. However, as hospitals reallocated resources to manage COVID-19 caseloads, non-emergency clinical services—including routine genetic testing and follow-up visits for patients affected by Giant Axonal Neuropathy—faced postponements and cancellations. This created significant enrollment gaps in early-stage and later-phase studies, delaying data readouts and pushing back projected timelines for regulatory filings.

Across academic and private research sites, travel restrictions and social distancing mandates hindered site initiation and monitoring visits, forcing sponsors to pivot toward remote trial management. While virtual platforms allowed for teleconsultations and electronic consent procedures, biomarker sample collection remained challenging due to limitations in local laboratory networks. Supply chain disruptions also affected availability of key reagents and vector manufacturing components, lengthening production cycles for investigational gene therapies.

Post-pandemic recovery traced a phased resumption of activities. Biotech and clinical research organizations implemented hybrid trial models that blend on-site visits with remote data capture, thereby improving patient retention and reducing infection risk. Regulatory agencies issued guidance to accommodate decentralized elements, allowing home nursing for infusion administration and local laboratory sample processing under strict standard operating procedures. Increased collaboration between specialized referral centers and community hospitals has expanded access for patients in remote areas.

Moving forward, strategic priorities need to emphasize resilient supply chains with geographically diversified manufacturing hubs, adoption of digital health technologies for continuous monitoring of neurologic endpoints, and flexible trial designs that can accommodate public health emergencies. Partnerships with telemedicine providers and patient advocacy groups will be crucial to maintain recruitment momentum and ensure continuity in rare disease studies even under unprecedented constraints.

Geographical Regions with Highest Value Concentration in the Giant Axonal Neuropathy Market

North America remains the leading region in terms of monetary allocation and therapeutic activity for Giant Axonal Neuropathy. A well-established ecosystem of rare disease networks, specialized academic research centers, and supportive reimbursement pathways underpins high per-patient spending on advanced gene therapy programs. The presence of prominent genomic and vector manufacturing facilities, coupled with favorable regulatory frameworks for expedited review of regenerative and cellular therapies, has attracted significant investment from biotech and venture capital. Patient advocacy organizations in the United States and Canada also play an active role in driving awareness, securing funding for natural history registries, and facilitating access to compassionate use programs.

In Europe, the market shows robust value concentration across the largest economies, driven by harmonized orphan drug regulations and publicly funded healthcare systems that reimburse innovative gene-based treatments. Countries such as Germany, France, Italy, and the United Kingdom are focal points for multicenter clinical trials due to the availability of centralized neuromuscular referral units and established biobank networks. Insurance mechanisms and government grants support early access initiatives that foster uptake of novel therapies upon conditional approval. Cross-border collaboration through pan-European consortia further enhances trial recruitment and resource sharing.

Japan and select nations in the Asia-Pacific region also contribute substantially to market value. Japan’s pioneering stance on regenerative medicine policies, including the conditional marketing authorization route, has accelerated clinical translation of candidate treatments for hereditary neuropathies. South Korea and Taiwan have demonstrated growing capabilities in vector production and clinical research infrastructure. Additionally, increasing public and private funding in China aims to build out trial site networks and strengthen rare disease patient registries, positioning key urban centers as high-value hubs.

Across these high-value regions, investment is largely concentrated in centers of excellence that combine research, clinical care, and manufacturing capabilities. Strategic alliances among local biotech firms, contract research organizations, and healthcare institutions further consolidate value in these geographic clusters.

Fastest Growing Region for the Giant Axonal Neuropathy Market

Among global territories, the Asia-Pacific region has emerged as the fastest expanding market for therapies targeting Giant Axonal Neuropathy. This rapid acceleration is fueled by multiple factors, including strengthened rare disease legislation, increasing governmental support for advanced therapy development, and a surge in collaborations between domestic biotech companies and international research sponsors. Nations such as China, India, and South Korea have streamlined regulatory pathways to attract global clinical trials, offering incentives like reduced approval timelines and fee waivers for orphan disease protocols. These policy measures have dramatically shortened the initiation-to-startup interval for gene therapy studies in the region.

Health authorities across Asia-Pacific are also investing heavily in specialized treatment centers and genomic screening programs designed to facilitate early diagnosis of hereditary neuropathies. Expanded newborn screening initiatives and improved public awareness campaigns have elevated case detection rates, consequently increasing the pool of eligible trial participants. Moreover, the development of regional contract manufacturing organizations with capabilities in viral vector production has mitigated previous supply chain constraints, enabling local sponsors to accelerate therapy scale-up and distribution efforts.

The increasing number of investigator-initiated studies, supported by both academic grants and private capital, has diversified the clinical research landscape. Virtual patient engagement platforms and mobile health solutions have further contributed to enrollment growth by overcoming geographic barriers and reducing travel burdens. As a result, enrollment targets for mid-stage and late-stage studies in Asia-Pacific are being met more rapidly compared to other regions.

Additionally, the competitive cost structure for clinical operations in countries like India provides economic advantages, attracting late-phase trials that require larger patient cohorts. Emerging markets in Southeast Asia and Latin America are also aspiring to replicate this growth trajectory by enhancing regulatory harmonization and forging partnerships with global rare disease alliances. Collectively, these dynamics position Asia-Pacific as the most dynamic and fastest growing territory in the current Giant Axonal Neuropathy landscape.

‣ Get More Insights On: Giant Axonal Neuropathy (GAN) Market

‣ Get this Report in Japanese Language: 巨大軸索性神経障害（GAN）市場

‣ Get this Report in Korean Language: 거대축삭신경병증(GAN)시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)